Chemotherapy as a possible trigger for the myocardial lipomatosis development
https://doi.org/10.18705/1607-419X-2021-27-6-706-712
Abstract
This article presents a clinical case of an asymptomatic myocardial damage associated with the chemotherapy. Myocardial lipomatosis developed in a 23-year-old patient with cancer of the right breast after 4 AC chemotherapy cycles. The death resulted from the rupture of a 14 cm saccular aneurysm of the internal carotid artery. This article presents both the data of instrumental and laboratory tests and pathomorphological analysis.
About the Authors
A. A. Avagimyan
Yerevan State Medical University named after M. Heratsi
Armenia
Armenia
MD, Lecturer, Pathological Anatomy Department, Resident in Internal Medicine
2 Koryun street, Yerevan 0025, Armenia
L. G. Mkrtchyan
Yerevan State Medical University named after M. Heratsi
Armenia
Armenia
MD, Head, Cardiology Department
2 Koryun street, Yerevan 0025, Armenia
N. B. Kononchuk
City Clinical Emergency Hospital
Belarus
Belarus
MD, PhD, Head, Department of Cardiology
Minsk
L. V. Kaktursky
Research Institute of Human Morphology
Russian Federation
Russian Federation
MD, PhD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, Scientific Director
Moscow
L. Agati
Sapienza — University of Rome
Italy
Italy
MD, PhD in Cardiovascular Medicine, Professor, Department of Cardiovascular, Respiratory, Nephrological and Geriatric Sciences
Rome
References
1. Anker MS, Lena A, Hadzibegovic S, Belenkov Y, Bergler-Klein J, A de Boer R et al. Modern-day cardio-oncology: a report from the 'Heart Failure and World Congress on Acute Heart Failure 2018. ESC Heart Fail. 2018;5(6):1083–1091.
2. Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26. doi:10.3389/fcvm.2020.00026
3. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945–1960. doi:10.1002/ejhf.1920
4. Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22(11):1966–1983. doi:10.1002/ejhf.2017
5. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32(2):302–14. doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2
6. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A et al. ESMO Guidelines Committee. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–190. doi:10.1016/j.annonc.2019.10.023
7. López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720–1729. doi:10.1093/eurheartj/ehaa006
8. Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971–977. doi:10.1136/heartjnl-2017-312103
9. Renu K, Abilash V G, Tirupathi Pichiah PB, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy — an update. Eur J Pharmacol. 2018;818:241–253. doi:10.1016/j.ejphar.2017.10.043
10. Avagimyan A, Kakturskiy L, Heshmat-Ghahdarijani K, Pogosova N, Sarrafzadegan N. Anthracycline associated disturbances of cardiovascular homeostasis. Current Problems in Cardiology. 2021;100909. doi:10.1016/j.cpcardiol.2021.100909
11. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85(3):1093–1129. doi:10.1152/physrev.00006.2004
12. Taegtmeyer H, Lam T, Davogustto G. Cardiac metabolism in perspective. Compr Physiol. 2016;6(4):1675–1699. doi:10.1002/cphy.c150056
Review
For citations:
Avagimyan A.A., Mkrtchyan L.G., Kononchuk N.B., Kaktursky L.V., Agati L. Chemotherapy as a possible trigger for the myocardial lipomatosis development. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2021;27(6):706-712. (In Russ.) https://doi.org/10.18705/1607-419X-2021-27-6-706-712
Views:
8251
Email this article 